The predictive value of FDG-PET-CT early during (chemo-)radiotherapy for local control of advanced stage head and neck cancer

The predictive value of FDG-PET-CT early during (chemo-)radiotherapy for local control of advanced stage head and neck cancer - PETPRED study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32415

Enrollment

Registered

2007-12-12

Start date

2008-01-24

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer head and neck squamous cell carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients with resectable advanced (stage III and IV) HNSCC scheduled for primary non-surgical treatment (radiotherapy with or without chemotherapy) with curative intent.

Exclusion criteria

Exclusion criteria: technically inoperable tumor

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy of FDG-PET-CT applied 2 weeks after the start of primary radiotherapy (with or without chemotherapy) for resectable HNSCC to predict local failure in the primary and cervical node metastases.	—

Secondary

Measure	Time frame
* FDG uptake level pretreatment * Residual FDG uptake level after 14 days of therapy * Change of FDG uptake .	—

Countries

Netherlands

Outcome results